Mechanisms of resistance to mTOR inhibitors

被引：35

作者：

Formisano, Luigi ^{[1
]}

Napolitano, Fabiana ^{[1
]}

Rosa, Roberta ^{[1
]}

D'Amato, Valentina ^{[1
]}

Servetto, Alberto ^{[1
]}

Marciano, Roberta ^{[1
]}

De Placido, Pietro ^{[1
]}

Bianco, Cataldo ^{[2
]}

Bianco, Roberto ^{[1
]}

机构：

[1] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy

[2] Univ Catanzaro Magna Graecia, Dept Expt & Clin Med, I-88100 Catanzaro, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 147卷

关键词：

mTOR inhibitors; Mechanisms of resistance; Predictive factors; MAMMALIAN TARGET; BREAST-CANCER; ANTITUMOR-ACTIVITY; RAPAMYCIN MTOR; EVEROLIMUS; PATHWAYS; GROWTH; CELLS; NVP-BEZ235; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.102886

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In several tumors the PI3K/AKT/mTOR pathway is frequently disrupted, an event that results in uncontrolled cell proliferation and tumor growth. Through the years, several compounds have been developed to inhibit the pathway at different steps: the mammalian target of rapamycin (mTOR) seemed to be the most qualified target. However, this kinase has such a key role in cell survival that mechanisms of resistance are rapidly developed. Nevertheless, clinical results obtained with mTOR inhibitors in breast cancer, renal cell carcinoma, neuroendocrine tumors and mantle cell lymphoma push oncologists to actively further develop these drugs, maybe by better selecting the population to which they are offered, through the research of predictive factors of responsiveness. In this review, we aim to describe mechanisms of resistance to mTOR inhibitors, from preclinical and clinical perspectives.

引用

页数：11

共 140 条

[1] The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy [J].